Market News AIOpen the app

Roche and Genprex found new results that may help spot patients for gene therapy in lung cancer.

TrialRead the original at prlog.org
Good for GNPX

The lab findings may help Genprex identify patients more likely to benefit from its gene therapy, supporting its Roche work. But testing is not complete, and use in clinical programs remains only a possibility.

GNPX · Genprex, Inc.

AI read · Good for GNPX

The AI's read

A marker that helps select patients could help Genprex match its treatment to those more likely to benefit. The study used lab models, not reported patient results. Genprex still expects to finish test validation by the end of 2026, and use in clinical programs remains a possibility.

Get alerts for GNPX

Follow Genprex, Inc. (GNPX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GNPX
Free on the App Store and Google Play, or on the web.